Triple Negative Breast Cancer

This guide provides practical information that will assist clinicians involved in the diagnosis, assessment, treatment, and follow-up care of patients with triple-negative breast cancer. After opening chapters on the pathologic evaluation, clinical presentation, genetics, and imaging features, the full range of current treatment approaches is thoroughly reviewed from a multidisciplinary perspective. Readers will find up-to-date information and guidance on surgical management, radiation therapy, tailored adjuvant therapy, neoadjuvant treatment, systemic treatment for metastatic disease, molecular profiling, and targeted therapy. The coverage is completed by discussion of special issues in young women with triple-negative breast cancer and individualization of the management approach in older patients affected with the disease. All healthcare professionals who care for patients with triple-negative breast cancer will find the book to be an invaluable source of expert advice on the issues faced in real-world practice.

After her diagnosis of hormone-negative breast cancer, health journalist Patricia Prijatel did what any reporter would do: start investigating the disease, how it occurs, how it's treated, and how to keep it from recurring. While she learned that important research on triple-negative breast cancer (TNBC) was emerging, she found a noticeable lack of resources on the disease, which differs from hormone-positive breast cancer in important ways, including prognosis and treatment options. Triple-negative breast cancer disproportionately affects younger women and African-American women-and some forms of it can be more dangerous than other types of breast cancer. But there are many reasons to be hopeful, as Prijatel shows in this book. Surviving Triple-Negative Breast Cancer delivers research-based information on the biology of TNBC; the role of genetics, family history, and race; how to navigate treatment options; understanding a pathology report; and a plethora of strategies to reduce the risk of recurrence, including diet and lifestyle changes. In clear, approachable language, Prijatel provides a fact-filled guide based on a vast array of scientific studies. Woven throughout the book are stories of women who have faced TNBC. These are mothers, wives, daughters, and sisters who went through a variety of medical treatments and then got on with life--one competes in triathlons, two had babies after being treated with chemo, one got remarried in her 50s, and one just celebrated the 30th birthday of the son she was nursing when she was diagnosed. Writing with honesty and humor, Prijatel delivers an inspiring message--that TNBC is a disease to take seriously, with proper and occasionally aggressive treatment, but it is not automatically a killer. Most women diagnosed with the disease survive and go on to live full lives. Surviving Triple-Negative Breast Cancer is a roadmap for women who want to be empowered through their treatment and recovery.

This book discusses the current state of cancer pathway as it is relevant to sub-Saharan Africa and highlights differences in epidemiology and the underlying problems with management. It outlines the current practice and opinions in all forms of cancer, also highlighting future prospects. Starting by providing background information on the epidemiology and genomic variations, the book then goes on to look at Infection-related cancers and continues to prostate GI, breast cancer and ovarian and cervical cancer. The last part of the book focuses on delivery of affordable and accessible care. Palliative services and primary and transnational research, as well as clinical trials are also discussed. Written by a team of authors based in the UK, Nigeria, South Africa and the US. this book offers an overview of the current state and challenges of cancer care in sub-Saharan Africa, and it would be valuable to policy makers, researchers, funding organisations, and can be an adjunct to standard text books for students, residents and established doctors.

Approximately10-20% of breast cancer patients are diagnosed with triple-negative breast cancer. 100 Questions & Answers About Triple Negative Breast Cancer provides authoritative and practical answers to the most common questions asked by patients and their loved ones. This easy-to-read book is a comprehensive guide to the basics of triple negative breast cancer, risk factors and prevention, diagnosis, treatment, survivorship, and life after diagnosis. Written by renowned medical experts on the topic, 100 Questions & Answers About Triple Negative Breast Cancer is an invaluable resource for anyone coping with the physical and emotional turmoil of this challenging type of breast cancer.

Despite recent advances in adjuvant therapies of cancer, the regi mens of postoperative adjuvant chemotherapy treatment which are presently available fail to cure the majority of cancer patients. Pre operative (neoadjuvant) chemotherapy represents a new approach in drug scheduling, based on sound theoretical, pharmacokinetic, and experimental principles. The preoperative timing of chemotherapy before definitive sur gery is not a minor change in the therapy of cancer. To be successful, large numbers of practitioners and their patients must participate. Substantial alterations of many aspects of the present management of cancer will have to follow. Therefore, before such therapy can be fully and routinely implemented, results of the novel treatment and its rationale have to be carefully evaluated. In preoperative treatment, other features will likely gain impor tance. For the first time, clinicians have a chance to follow the in vivo response of the tumor exposed to preoperative chemotherapy. The subsequent histological assessment of the tumor sample may likely become an important prognostic guide, permitting more re fined individual approaches to the planning of postoperative adju vant treatment. The value of such a treatment strategy can already be appreciated in the clinical setting, as seen from the therapy of osteosarcoma. Furthermore, preoperative chemotherapy might render previously inoperable tumors operable and hence resectable with a curative intention. The preoperative reduction of tumor bulk may also effectively decrease the need for more radical operations, permitting a more uniform adoption of conservative surgery.

Approximately10-20% of breast cancer patients are diagnosed with triple-negative breast cancer. The updated second edition of 100 Questions & Answers About Triple Negative Breast Cancer provides authoritative and practical answers to the most common questions asked by patients and their loved ones. This easy-to-read book is a comprehensive guide to the basics of triple negative breast cancer, risk factors and prevention, diagnosis, treatment, survivorship, and life after diagnosis. Written by renowned medical experts on the topic, 100 Questions & Answers About Triple Negative Breast Cancer is an invaluable resource for anyone coping with the physical and emotional turmoil of this challenging type of breast cancer.

Triple-negative breast cancer (TNBC) represents a challenge clinically due to the lack of actionable targets coupled with an aggressive disease course and a worse prognosis compared to other breast cancer subtypes. This book covers aspects of TNBC ranging from epidemiology, biology, molecular classification, to currently available and potentially new therapeutic options for TNBC. This book contains a range of recommended resources, including recent reviews, schematic illustrations, and information for patients with TNBC. Individuals including researchers and educators, practitioners, pharmaceutical professionals, patients as well as their family members will find this book useful.

This book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoeconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic.